Advertisement
Screener

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Research and Development in Process

2.8 / 5 stars · 68/120 Roast Me

INTEGRA LIFESCIENCES HOLDINGS CORP Research and Development in Process

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported Research and Development in Process of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.

Discontinued › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentInProcess · last filed 2022-02-24

  • INTEGRA LIFESCIENCES HOLDINGS CORP research and development in process for the quarter ending 2020-12-31 was $0.00, a 100.00% decline year-over-year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP research and development in process for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP research and development in process for the quarter ending 2019-12-31 was $5.03M.
  • INTEGRA LIFESCIENCES HOLDINGS CORP research and development in process for the quarter ending 2019-09-30 was $59.89M.
  • INTEGRA LIFESCIENCES HOLDINGS CORP research and development in process for fiscal 2021 was $0.00.
  • INTEGRA LIFESCIENCES HOLDINGS CORP research and development in process for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
  • INTEGRA LIFESCIENCES HOLDINGS CORP research and development in process for fiscal 2019 was $64.92M.
  • INTEGRA LIFESCIENCES HOLDINGS CORP research and development in process for fiscal 2018 was $0.00.
Period endResearch and Development in Process 3 monthResearch and Development in Process 6 monthResearch and Development in Process 9 monthResearch and Development in Process 9 month as first filedResearch and Development in Process 12 month
2021-12-31$0.00
10-K · filed 2022-02-24
2020-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$0.00
derived: sum of 2 quarters · filed 2022-02-24
$0.00
10-K · filed 2022-02-24
2020-09-30$0.00
10-Q · filed 2020-10-29
$0.00
10-Q · filed 2020-10-29
2019-12-31$5.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24
$64.92M
derived: sum of 2 quarters · filed 2022-02-24
$64.92M
10-K · filed 2022-02-24
2019-09-30$59.89M
10-Q · filed 2020-10-29
$59.89M
10-Q · filed 2020-10-29
$61.57M
10-Q · filed 2019-10-25
2018-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23
$0.00
derived: sum of 2 quarters · filed 2021-02-23
$0.00
10-K · filed 2021-02-23
2018-09-30$0.00
10-Q · filed 2019-10-25
$0.00
10-Q · filed 2019-10-25
2017-12-31$0.00
10-K · filed 2020-02-21
2010-12-31$0.00
10-K · filed 2011-02-24
2009-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-27
$277.00K
10-K · filed 2012-02-27
2009-09-30$277.00K
10-Q · filed 2010-10-28
2008-12-31$25.24M
10-K · filed 2011-02-24

Similar stocks

Stock NameCountryMarket CapPE Ratio
ARTIVION, INC. (AORT)United States$1.123B-345.09
IRADIMED CORP (IRMD)United States$1.089B52.92
TANDEM DIABETES CARE INC (TNDM)United States$1.059B-16.57
PROCEPT BioRobotics Corp (PRCT)United States$1.001B-11.77
Beta Bionics, Inc. (BBNX)United States$0.979B-9.66
Alphatec Holdings, Inc. (ATEC)United States$1.531B-12.14
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)United States$1.535B-9.02
SpyGlass Pharma, Inc. (SGP)United States$0.925B
SI-BONE, Inc. (SIBN)United States$0.830B-49.82
MIMEDX GROUP, INC. (MDXG)United States$0.687B89.92